CD19-redirected chimeric antigen receptor (CD19 CAR) T cell in the clinical treatment of human non-Hodgkin’s lymphoma and acute lymphoblastic leukemia

Received: 11-Mar-2019 Accepted Date: May 14, 2019; Published: 21-Jun-2019

Citation: Jazirehi AR, Knott JD, Chiuzzi E. CD19-redirected Chimeric Antigen Receptor (CD19 CAR) T Cell in the Clinical Treatment of Human Non-Hodgkin’s Lymphoma and Acute Lymphoblastic Leukemia. J Blood Disord Treat. 2019;2(1):7-16.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Retraction Note

The article entitled “CD19-redirected chimeric antigen receptor (CD19 CAR) T cell in the clinical treatment of human non-Hodgkin’s lymphoma and acute lymphoblastic leukemia,” has been accepted for publication in the Journal of Blood Disorders and Treatment considering the statements provided in the article as personal opinion of the author which was found not having any conflict or biasness towards anything. As the article was a perspective one, information provided by the author was considered as an opinion to be expressed through publication.

Publisher took decision to make the article online solely based on the reviewers suggestion which considered the article not but a personal opinion of the author. However, it is found that the author have some personal concerns and issues, therefore, being retracted from the journal.